ADVERTISEMENT
ICICI Securities: Dr. Reddy’s Settles Revlimid Litigation With Celgene
Dr. Reddy’s can generate cumulative sales and PAT of $2.5 billion and $1.6 billion over this shared exclusivity period.
18 Sep 2020, 11:16 PM IST 
People chat in the lobby of Innovation Plaza building, on Dr. Reddy’s Laboratories Ltd. campus in Hyderabad. (Photographer: Prashanth Vishwanathan/Bloomberg)
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
I’m already a Subscriber Sign In
To continue reading this storySubscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
